Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 8/2016

01-08-2016 | Review Article

Psoriatic arthritis and psoriasis: differential diagnosis

Authors: Maddalena Napolitano, Francesco Caso, Raffaele Scarpa, Matteo Megna, Angela Patrì, Nicola Balato, Luisa Costa

Published in: Clinical Rheumatology | Issue 8/2016

Login to get access

Abstract

Psoriasis frequency ranges from 1 to 3 % in white population, and arthritis occurs in 10–40 % of psoriasis patients, representing a relevant health issue. Psoriatic arthritis (PsA) is an inflammatory arthropathy, associated with psoriasis, in which ocular-, intestinal-, metabolic-, and cardiovascular-related manifestations can variably coexist. In order to favor early PsA and psoriasis diagnosis, it is crucial to rule out other conditions that can resemble the disease and delay appropriate therapeutic approach. Therefore, the aim of this review is to focus on PsA and psoriasis differential diagnosis.
Literature
1.
2.
Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR (2015) Association of psoriatic disease with Uveitis: a Danish nationwide cohort study. JAMA Dermatol 151:1200–5PubMedCrossRef
3.
Scarpa R, Manguso F, D’Arienzo A, D’Armiento FP, Astarita C, Mazzacca G, Ayala F (2000) Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 27:1241–6PubMed
4.
Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–5PubMedCrossRef
5.
Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA et al (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–53PubMedCrossRef
6.
Shen J, Shang Q, Li EK, Leung YY, Kun EW, Kwok LW, Li M, Li TK, Zhu TY, Yu CM, Tam LS (2015) Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther 17:75PubMedPubMedCentralCrossRef
7.
Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L (2016) Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 12:315–31PubMedCrossRef
8.
Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD (2009) IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183:3170–6PubMedPubMedCentralCrossRef
9.
van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, Gerlag DM, Tak PP (2014) Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther 16:426PubMedPubMedCentralCrossRef
10.
van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP (2006) Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 65:1551–7PubMedPubMedCentralCrossRef
11.
Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, Lunardi F, Calabrese F, Vezzù M, Dainese S, Molena B, Scanu A, Nardacchione R, Rubaltelli L, Dayer JM, Punzi L (2010) Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther 12:R148PubMedPubMedCentralCrossRef
12.
Nestle FO, Turka LA, Nickoloff BJ (1994) Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 94:202–9PubMedPubMedCentralCrossRef
13.
Kirkham BW, Kavanaugh A, Reich K (2014) Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 141:133–42PubMedPubMedCentralCrossRef
14.
Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S (2014) Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 71:141–50PubMedCrossRef
15.
Isailovic N, Daigo K, Mantovani A, Selmi C (2015) Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun 60:1–11PubMedCrossRef
16.
Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Felicetti M, Frallonardo P, Facco M, Boso D, Molena B, Zambello R, Ramonda R, Cozzi F, Scarpa R, Basso G, Semenzato G, Dayer JM, Doria A, Punzi L (2015) Ex vivo signaling protein mapping in T lymphocytes in the psoriatic arthritis joints. J Rheumatol Suppl 93:48–52PubMedCrossRef
17.
Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Facco M, Boso D, Gatto M, Felicetti M, Frallonardo P, Ramonda R, Piva L, Zambello R, Agostini C, Scarpa R, Basso G, Semenzato G, Dayer JM, Punzi L, Doria A (2015) Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol 34:1571–80PubMedCrossRef
18.
Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer JM (2014) JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 58:61–9PubMedCrossRef
19.
Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B (2015) Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther 17:249PubMedPubMedCentralCrossRef
20.
McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, Feldmann M, Williams RO, Brennan FM (2010) Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 12(3):R107PubMedPubMedCentralCrossRef
21.
Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159:842–55PubMedCrossRef
22.
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311–28PubMedCrossRef
23.
Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41:545–68PubMedCrossRef
24.
Caso F, Costa L, Atteno M, Del Puente A, Cantarini L, Lubrano E, Scarpa R (2014) Simple clinical indicators for early psoriatic arthritis detection. Springerplus 3:759PubMedPubMedCentralCrossRef
25.
Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G, Cauli A et al (2012) Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 39:849–55PubMedCrossRef
26.
27.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–73PubMedCrossRef
28.
Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N (2012) The ClASsification for psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39:154–6PubMedCrossRef
29.
30.
Ficjan A, Husic R, Gretler J, Lackner A, Graninger WB, Gutierrez M, Duftner C, Hermann J, Dejaco C (2014) Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). Arthritis Res Ther 16:476PubMedPubMedCentralCrossRef
31.
Fiocco U, Stramare R, Coran A, Grisan E, Scagliori E, Caso F, Costa L, Lunardi F, Oliviero F, Bianchi FC, Scanu A, Martini V, Boso D, Beltrame V, Vezzù M, Cozzi L, Scarpa R, Sacerdoti D, Punzi L, Doria A, Calabrese F, Rubaltelli L (2015) Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol 34:1903–12PubMedCrossRef
32.
Soscia E, Sirignano C, Catalano O, Atteno M, Costa L, Caso F, Peluso R, Bruner V, Aquino MM, Del Puente A, Salvatore M, Scarpa R (2012) New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 89:49–53PubMedCrossRef
33.
Tan AL, Fukuba E, Halliday NA, Tanner SF, Emery P, Mc Gonagle D (2015) High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Ann Rheum Dis 74:185–9PubMedCrossRef
34.
Gutierrez M, Filippucci E, De Angelis R, Filosa G, Kane D, Grassi W (2010) A sonographic spectrum of psoriatic arthritis: “the five targets”. Clin Rheumatol 29:133–42PubMedCrossRef
35.
Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E, Cozzi L, Di Maggio A, Nardacchione R, Molena B, Felicetti M, Gazzola K, Stramare R, Rubaltelli L, Accordi B, Costa L, Roux-Lombard P, Punzi L, Dayer JM (2013) Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 80:165–70PubMedCrossRef
36.
Mandl P, Navarro-Compán V, Terslev L et al (2015) European league against rheumatism (EULAR). EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 74:1327–39PubMedCrossRef
37.
Coates LC, Ritchlin CT, Kavanaugh AF (2014) GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol 41:1237–9PubMedCrossRef
38.
Caso F, Costa L, Del Puente A, Scarpa R (2015) Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opin Biol Ther 15:1–2PubMedCrossRef
39.
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64:1035–50PubMedPubMedCentralCrossRef
40.
Caso F, Cantarini L, Morisco F et al (2015) Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 15:641–50PubMedCrossRef
41.
Atteno M, Costa L, Matarese A et al (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 33:543–7PubMedPubMedCentralCrossRef
42.
Costa L, Caso F, Atteno M et al (2014) Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33:273–6PubMedCrossRef
43.
Sanduzzi A, Bocchino M, Atteno M et al (2012) Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl 89:82–5PubMedCrossRef
44.
Scarpa R, Costa L, Atteno M, Del Puente A, Caso F, Moll JM (2013) Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother 14:2311–3PubMedCrossRef
45.
Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L (2016) Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs 21:69–79PubMedCrossRef
46.
Atzeni F, Costa L, Caso F et al (2015) Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis. J Rheumatol Suppl 93:79–81PubMedCrossRef
47.
Picchianti-Diamanti A, Germano V, Ferlito C, Migliore A, D’Amelio R, Laganà B (2010) Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept. Qual Life Res 19:821–6PubMedCrossRef
48.
49.
Gladman DD (2015) Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am 41:569–79PubMedCrossRef
50.
Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ (1994) Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 33:834–9PubMedCrossRef
51.
Scarpa R, Oriente P, Pucino A, Vignone L, Cosentini E, Minerva A, Biondi Oriente C (1988) The clinical spectrum of psoriatic spondylitis. Br J Rheumatol 27:133–7PubMedCrossRef
52.
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med 62:127–41PubMed
53.
Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M, Ayala F, D’Arienzo A, Oriente P (2003) Clinical and genetic aspects of psoriatic arthritis “sine psoriasis”. J Rheumatol 30:2638–40PubMed
54.
55.
Höhler T, Märker-Hermann E (2001) Psoriatic arthritis: clinical aspects, genetics, and the role of T cells. Curr Opin Rheumatol 13:273–9PubMedCrossRef
56.
Lubrano E, Parsons WJ, Marchesoni A, Olivieri I, D’Angelo S, Cauli A, Caso F, Costa L, Scarpa R, Brunese L (2015) The definition and measurement of axial psoriatic arthritis. J Rheumatol Suppl 93:40–2PubMedCrossRef
57.
McEwen C, DiTata D, Lingg C, Porini A, Good A, Rankin T (1971) Ankylosing spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter’s disease. A comparative study. Arthritis Rheum 14:291–318PubMedCrossRef
58.
Helliwell PS, Hickling P, Wright V (1998) Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 57:135–40PubMedPubMedCentralCrossRef
59.
Poggenborg RP, Østergaard M, Terslev L (2015) Imaging in psoriatic arthritis. Rheum Dis Clin North Am 41:593–613PubMedCrossRef
60.
Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis--‘DIP or not DIP revisited’. Rheumatology (Oxford) 42:1469–76CrossRef
61.
Jevtic V, Lingg G (2012) Differential diagnosis of rheumatoid and psoriatic arthritis at an early stage in the small hand and foot joints using magnetic resonance imaging. Handchir Mikrochir Plast Chir 44:163–70PubMedCrossRef
62.
Balakrishnan C, Madnani N (2013) Diagnosis and management of psoriatic arthritis. Indian J Dermatol Venereol Leprol 79(Suppl 7):S18–24PubMedCrossRef
63.
Olivieri I, D’Angelo S, Palazzi C, Padula A (2014) Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 10:531–42PubMedCrossRef
64.
Cervini C, Leardini G, Mathieu A, Punzi L, Scarpa R (2005) Psoriatic arthritis:epidemiological and clinical aspects in a cohort of 1.306 Italian patients. Reumatismo 57:283–90PubMed
65.
Perez-Alamino R, Garcia-Valladares I, Cuchacovich R, Iglesias-Gamarra A, Espinoza LR (2014) Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease? Rheumatol Int 34:1211–6PubMedCrossRef
66.
Del Puente A, Esposito A, Parisi A, Atteno M, Montalbano S, Vitiello M, Esposito C, Bertolini N, Foglia F, Costa L, Scarpa R (2012) Osteoporosis and psoriatic arthritis. J Rheumatol Suppl 89:36–8PubMedCrossRef
67.
Del Puente A, Esposito A, Costa L, Benigno C, Del Puente A, Foglia F, Oriente A, Bottiglieri P, Caso F, Scarpa R (2015) Fragility fractures in patients with psoriatic arthritis. J Rheumatol Suppl 93:36–9PubMedCrossRef
68.
Helliwell PS, Hetthen J, Sokoll K, Green M, Marchesoni A, Lubrano E, Veale D, Emery P (2000) Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum 43:865–71PubMedCrossRef
69.
Khan M, Schentag C, Gladman DD (2003) Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 30:1022–6PubMed
70.
van Tubergen A, Weber U (2012) Diagnosis and classification in spondyloarthritis: identifying a chameleon. Nat Rev Rheumatol 8:253–61PubMedCrossRef
71.
72.
Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, Biondi Oriente C (1984) Psoriatic arthritis in psoriatic patients. Br J Rheumatol 23:246–50PubMedCrossRef
73.
Oriente P, Biondi-Oriente C, Scarpa R (1994) Psoriatic arthritis. Clin Manifestations Baillieres Clin Rheumatol 8:277–94PubMedCrossRef
74.
75.
Peter JB, Pearson CM, Marmor L (1966) Erosive osteoarthritis of the hands. Arthritis Rheum 9:365–88PubMedCrossRef
76.
Swezey RL, Alexander SJ (1971) Erosive osteoarthritis and the main en lorgnette deformity (opera glass hand). Arch Intern Med 128:269–72PubMedCrossRef
77.
Smukler NM, Edeiken J, Giuliano VJ (1971) Ankylosis in osteoarthritis of the finger joints. Radiology 100:525–30PubMedCrossRef
78.
McGonagle D, Hermann KG, Tan AL (2015) Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford) 54:29–38CrossRef
79.
Haddad A, Johnson SR, Somaily M, Fazelzad R, Kron AT, Chau C, Chandran V (2015) Psoriatic arthritis mutilans: clinical and radiographic criteria. Syst Rev J Rheumatol 42:1432–8CrossRef
80.
Jadon DR, Shaddick G, Tillett W, Korendowych E, Robinson G, Waldron N, Cavill C, McHugh NJ (2015) Psoriatic arthritis mutilans: characteristics and natural radiographic history. J Rheumatol 42:1169–76PubMedCrossRef
81.
Gudbjornsson B, Ejstrup L, Gran JT, Iversen L, Lindqvist U, Paimela L, Ternowitz T, Ståhle M (2013) Psoriatic arthritis mutilans (PAM) in the Nordic countries: demographics and disease status. The Nordic PAM study. Scand J Rheumatol 42:373–8PubMedCrossRef
82.
83.
Omland SH, Gniadecki R (2015) Psoriasis inversa: a separate identity or a variant of psoriasis vulgaris? Clin Dermatol 33:456–61PubMedCrossRef
84.
Kim BY, Choi JW, Kim BR, Youn SW (2015) Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index. Ann Dermatol 27:26–31PubMedPubMedCentralCrossRef
85.
Johnson MA, Armstrong AW (2013) Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol 44:166–72PubMedCrossRef
86.
Karadag AS, Kavala M, Ozlu E, Ozkanlı S, Zindancı İ, Turkoglu Z (2016) Erythrodermic pityriasis rubra pilaris: dramatic response to Infliximab therapy. Indian J Dermatol Venereol Leprol 82:112PubMedCrossRef
87.
Amann PM, Susic M, Glüder F, Berger H, Krapf W, Löffler H (2015) Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol 95:329–31PubMedCrossRef
88.
Yun CH, Kim JS, Ryu HR, Kim JH, Baek JO, Lee JR, Roh JY (2016) Circumscribed juvenile pityriasis rubra pilaris responsive to alitretinoin. Dermatol Ther 29:81–3PubMedCrossRef
89.
90.
Kalra MG, Higgins KE, Kinney BS (2014) Intertrigo and secondary skin infections. Am Fam Physician 89:569–73PubMed
91.
Balato N, Di Costanzo L, Balato A (2009) Differential Diagnosis of Psoriasis. J Rheumatol. 36 Suppl 83.
92.
Panda M, Patro N, Jena M, Dash M, Mishra S (2014) Pityriasis rosea like drug rash—a need to identify the disease in childhood. J Clin Diagn Res 8:YD01–2PubMedPubMedCentral
93.
Guarneri F, Cannavò SP, Minciullo PL, Gangemi S (2015) Pityriasis rosea of Gibert: immunological aspects. J Eur Acad Dermatol Venereol 29:21–5PubMedCrossRef
94.
James W, Berger T, Elston D (2005) Andrews’ diseases of the skin: clinical dermatology (10th ed). Saunders. pp. 208–9.
95.
Clark GW, Pope SM, Jaboori KA (2015) Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician 91:185–90PubMed
96.
Hay RJ (2011) Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol 165(Suppl 2):2–8PubMedCrossRef
97.
Dessinioti C, Katsambas A (2013) Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 31:343–51PubMedCrossRef
98.
Zegpi MS, Ruiz FM, Porras NK (2015) Pityriasis lichenoides: case report and review of the literature. Rev Chil Pediatr 86:121–5PubMedCrossRef
99.
Errichetti E, Lacarrubba F, Micali G, Piccirillo A, Stinco G (2015) Differentiation of pityriasis lichenoides chronica from guttate psoriasis by dermoscopy. Clin Exp Dermatol 40:804–6PubMedCrossRef
100.
Brazzelli V, Carugno A, Rivetti N, Cananzi R, Barruscotti S, Borroni G (2013) Narrowband UVB phototherapy for pediatric generalized pityriasis lichenoides. Photodermatol Photoimmunol Photomed 29:330–3PubMedCrossRef
101.
Park JM, Jwa SW, Song M, Kim HS, Chin HW, Ko HC, Kim MB, Kim BS (2013) Is narrowband ultraviolet B monotherapy effective in the treatment of pityriasis lichenoides? Int J Dermatol 52:1013–8PubMedCrossRef
102.
103.
Benhamou CL, Chamot AM, Kahn MF (1988) Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 6:109–12PubMed
104.
Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, Compagnone A, Caso P, Frediani B, Galeazzi M, Punzi L, Cantarini L (2013) Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol 2013:513782PubMedPubMedCentralCrossRef
105.
Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal Osteoartic 54:187–96PubMed
106.
Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC (2001) Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 28:113–9PubMedCrossRef
Metadata
Title
Psoriatic arthritis and psoriasis: differential diagnosis
Authors
Maddalena Napolitano
Francesco Caso
Raffaele Scarpa
Matteo Megna
Angela Patrì
Nicola Balato
Luisa Costa
Publication date
01-08-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3295-9

Other articles of this Issue 8/2016

Clinical Rheumatology 8/2016 Go to the issue

Original Article

Tendon involvement in patients with gout: an ultrasound study of prevalence

Original Article

Evaluation of cardiac functions in juvenile systemic lupus erythematosus with two-dimensional speckle tracking echocardiography

Original Article

Differences in cardiovascular manifestations between ankylosing spondylitis patients with and without kyphosis

Original Article

Associations between ERAP1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis

Original Article

Characterization of copy number variants for CCL3L1 gene in rheumatoid arthritis for French trio families and Tunisian cases and controls

Original Article

Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits